Skip to main content
Premium Trial:

Request an Annual Quote

Biotech Incubator s War Chest Gets $2M Infusion

NEW YORK, Feb. 5 - Bioscience incubator LaunchCyte has secured $2 million in new funding, bringing its total capitalization to $4.6 million, the company said on Tuesday.


More than $1 million of that cash came from current investors, the company said. Investors include former Monsanto CEO Robert Shapiro and the Commonwealth of Pennsylvania.


LaunchCyte was founded in 2000 with the goal of propelling what it considers promising biotech companies to market. Its strategy is to identify biotech-based ideas, with a particular focus on bioinformatics technologies, and to supply seed money and help investigators begin and cultivate startups.


To date, the firm, based in Pittsburgh, has helped launch three companies: Morewood Molecular Sciences, focused on high-throughput screening and cancer diagnostics; genotyping firm Biodot; and sepsis therapeutic-research company Immunetrics.


LaunchCyte has said it hopes to create 25 companies within the next few years. 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.